Assess the Efficacy and Safety of INCB054707 in Participants
With Hidradenitis Suppurativa
Recruitment Status: Recruiting
Estimated Study Completion Date: July 28, 2022
HS Connect listed this: September 2020
Sponsor: Incyte Corporation
Information provided by (Responsible Party): Incyte Corporation
To evaluate the efficacy and safety of INCB054707 in participants with hidradenitis suppurativa over a 16-week placebo-controlled treatment period followed by a 36 -week open-label extension period.
Please link for complete trial details:
Location: Multiple US locations. Please see link provided above for all location details and to confirm your location is recruiting.
Contact: Incyte Corporation Call Center (US) Phone: 1.855.463.3463 Email:
Contact: Incyte Corporation Call Center (ex-US) Phone: +800 00027423 Email: